TABLE 4

Univariate Analysis and Multivariable Analysis of OS and rPFS in T-Naïve Patients

	Univariate analysis				Multivariable analysis^*
	OS		rPFS		OS		rPFS
Subgroup	HR	P	HR	P	HR	P	HR	P
Age: >70 y	1.23 (0.59–2.53)	0.584	0.68 (0.41–1.14)	0.142	NA	NA	0.71 (0.42–1.21)	0.212
Karnofsky performance status: ≤80	2.05 (0.99–4.26)	0.055	0.83 (0.49–1.39)	0.477	0.60 (0.22–1.66)	0.326	NA	NA
Baseline PSA: >60 ng/mL	2.40 (1.16–4.98)	0.019	1.88 (1.09–3.24)	0.024	1.41 (0.50–4.00)	0.521	1.01 (0.50–2.03)	0.977
Time from diagnosis to first ¹⁷⁷Lu-PRLT treatment: >5 y	0.42 (0.20–0.86)	0.018	0.59 (0.35–0.98)	0.040	0.72 (0.32–1.65)	0.439	0.71 (0.42–1.21)	0.205
Cumulative administered activity: >16 GBq	0.42 (0.21–0.86)	0.017	0.89 (0.53–1.49)	0.658	0.44 (0.18–1.10)	0.080	NA	NA
Bone metastases: yes	3.46 (1.05–11.42)	0.041	1.49 (0.77–2.86)	0.235	2.51 (0.70–8.97)	0.156	NA	NA
Visceral metastases: yes	1.56 (0.69–3.52)	0.285	2.08 (1.13–3.82)	0.018	NA	NA	2.30 (1.23–4.33)	0.009
Baseline hemoglobin: ≤7.5 mmol/L	2.96 (1.45–6.05)	0.003	1.76 (1.03–3.02)	0.039	1.22 (0.44–3.37)	0.706	1.28 (0.70–2.32)	0.428
Baseline ALP^*: ≥220 U/L	12.93 (4.98–33.60)	<0.001	4.03 (2.03–7.98)	<0.001	11.7 (2.92–47.15)	0.001	3.87 (1.55–9.70)	0.004